Further Notifications

Here you find all press releases and further notifications, as well as all events of Fraunhofer ITMP.

News / 14.10.2022

Successful first round of the »TheraNova« Summer School

The first Summer School of the Innovation Center »Innovative Therapeutics« (TheraNova) took place in Mainz, October 13 to October 14, 2022. Project updates were given by participating PhD students and clinician scientists from Johann Wolfgang Goethe University and the Fraunhofer Institutes ITMP and IGD, and invited speakers highlighted current developments in the fields of innovative therapeutics, personalized medicine and entrepreneurship.

Press Release / 26.9.2022

Opening of the Fraunhofer ITMP-TNM Early Clinical Trial Unit (ECTU)

The Fraunhofer Institute for Translational Medicine and Pharmacology ITMP opened an Early Clinical Trial Unit (ECTU) at the University Medical Center Göttingen (UMG) on September 15, 2022. The focus is on first clinical testing of compounds for the treatment of largely intractable (autoimmune) diseases of the central nervous system (CNS), such as multiple sclerosis or Parkinson's disease. The goal is a rapid and targeted implementation of scientific findings to diagnostics, therapies and prevention.

Press Release / 22.9.2022

Opening of the Fraunhofer ITMP and awarding of the Fraunhofer medal to former premier of the state of Hesse Volker Bouffier

On September 21, 2022, the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP was officially opened. The institute, which was already transferred to an independent Fraunhofer Institute at the beginning of last year, has since developed into an important component and leading institute of Fraunhofer health research. During the opening ceremony at the University Hospital Frankfurt, Volker Bouffier was also honored with the Fraunhofer Medal.

Press Release/News / 1.9.2022

REMEDi4ALL launches to drive the repurposing of medicines in Europe


The EU-funded project REMEDi4ALL willl make a major leap forward in drug repurposing, or finding new therapeutic option for existing drugs, in areas where there are high unmet medical needs. The 3 Fraunhofer institutes participating, Fraunhofer ITMP, Fraunhofer IZI and Fraunhofer SCAI, combine expertise in the realization of in-silico and in-vitro driven drug repurposing programs, the design of predictive in vivo models, the execution of clinical trials and algorithm development for the analysis of drug discovery data.

Press Release/News / 6.5.2022

Opening of the Fraunhofer ITMP laboratories at Roche in Penzberg


On May 6, 2022, the laboratories of the Fraunhofer ITMP site for immunology, infection and pandemic research in Penzberg/Munich were officially opened. The aim of the on-site research is to identify and characterize pandemic pathogens, develop new diagnostics and therapies, and better understand the role of the immune system in infectious diseases. Until the completion of their own building, the researchers will start their work in rented rooms on the campus of Roche's biotechnology center in Penzberg. 

Press Release / 5.5.2022

AIOLOS launches development of an early detection platform for epidemics


The Franco-German AIOLOS project (Artificial Intelligence Tools for Outbreak Detection and Response) has received approval to develop a digital platform designed to allow for early detection of new respiratory pathogens epidemics, monitor their spread and inform decisions on appropriate counter measures.

Sanofi in France and the Fraunhofer Institutes SCAI and ITMP in Germany lead the consortium, which includes four other French and German partners.

Research Divisions

Fraunhofer ITMP is organized in 3 cross-site research divisions.


Drug Discovery


From target to screening to lead optimization and formulation.


Preclinical Research


Translational cycles and OMICs analyses for characterization of biological mechanisms and novel targets.


Clinical Research


From „Proof-of-Concept“ to the characterization of established products: “Quality by Design” for successful translation of innovative ideas.

Innovation Areas

Fraunhofer ITMP is optimally interconnected internally as well as externally with other Fraunhofer institutes, universities and industry via the innovation areas. This is the prerequisite for transdisciplinary and flexible cooperation in the areas of new technologies, disease and treatment concepts.

Institute Locations


Locations of Fraunhofer ITMP


Fraunhofer ITMP, with its headquarters in Frankfurt am Main, currently has four additional institute locations in Hamburg, Göttingen, Berlin and Penzberg/Munich.


Headquarters of Fraunhofer ITMP

Frankfurt am Main


The site has strong expertise in pharmacology and clinical trials in immune-mediated diseases and pain. 


Discovery Research ScreeningPort



The site has strong expertise in high-throughput drug discovery (in silico, in vitro screening and drug repurposing) as well as a broad offering in "medical data science".


Translational Neuroinflammation and Automated Microscopy TNM


The site has strong expertise in high- and super-resolution microscopy techniques; as well as neuroinflammation and degenerative diseases.


Immunology and Allergology IA


The site has strong expertise in dermatology, allergology, and immunological mast cell-mediated inflammatory diseases of the skin.


Immunology, Infection and Pandemic Research IIP


The site has strong expertise in developing interventions to address the outbreak of new and spread of existing infectious diseases.